NasdaqGM:RLAYBiotechs
Relay Therapeutics (RLAY) Valuation Check After Advancing Zovegalisib Combination Into Phase 3 Development
Relay Therapeutics (RLAY) has drawn fresh attention after deciding to advance zovegalisib plus Pfizer’s atirmociclib into Phase 3 for PI3Ka-mutated, HR+/HER2- metastatic breast cancer, following early safety and response data in heavily pre-treated patients.
See our latest analysis for Relay Therapeutics.
The share price has been volatile around the latest zovegalisib update, with a 7 day share price return of negative 15.9%, following a 90 day share price return of 66.1% and a 1 year total...